WIM
VRTX icon

WealthPlan Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

WealthPlan Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,366
Closed -$635K – 283
2024
Q3 		$635K Buy
+1,366
New +$656K 0.06% 143

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

WealthPlan Investment Management's VRTX Position: Q4 2024 in Review

WealthPlan Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 1,366 shares — an estimated $635K sold.

WealthPlan Investment Management first reported a position in VRTX in Q3 2024 and held it in 1 quarter. The position peaked at $635K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • WealthPlan Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • WealthPlan Investment Management sold 1,366 Vertex Pharmaceuticals shares in Q4 2024, an estimated $635K.
  • WealthPlan Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • WealthPlan Investment Management's Vertex Pharmaceuticals position peaked at $635K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on WealthPlan Investment Management's 13F filing for Q4 2024, filed 30 Jan 2025.